OLR1 and atherosclerosis: Li et al. reported that by feeding atherosclerosis mice UA and rosuvastatin, there was a significant reduction in the necrotic core area in blood vessels, a decrease in atherosclerotic plaque area, and inhibition of NF-κB-mediated LOX-1 expression in vivo and in vitro through ROS production, which improved outcomes related to atherosclerosis (Li et al., 2018).